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Abstract
The increase in life expectancy leads to the possibility of development chronic diseases,
from special physiological conditions as occurs in the menopause, which is defined as
the permanent cessation of ovulation, marked by the end of menstruation. It has been
related to decreased ovarian function that occurs around an age of 45 years. This event
involves the reduction in estrogen production and may contribute to the development
of chronic‐degenerative diseases. Many diseases developed during menopause have
been  associated  with  oxidative  stress,  such  as  osteoporosis,  hot  flushes,  cognitive
impairment,  insulin  resistance,  dry  skin,  obesity,  and  cardiovascular  events.  The
knowledge about the participation of Nrf2 in diseases that occur during menopause is
very limited. Here, only diseases such as osteoporosis, cardiovascular diseases and dry
skin, which are present during menopause and its later stages have been described. The
Nrf2 pathway involves the participation of PI3K/Akt, MAPK, and eNOS, which act as
mediators for cytoprotection and antioxidation. Compounds such as equol, fitoestro‐
gens, alkyl cathecols, or curcumin could be offered as options to antioxidant treatment,
added the fact that they are present in fruits and vegetables which are rich in vitamins,
minerals  and  calcium,  thus  including  all  the  required  nutrients  for  an  adequate
nutrition.
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1. Introduction
Menopause is defined as the permanent cessation of menstruation by an year in a row, by
decreasing the estrogen production, as a consequence of ovarian dysfunction. It occurs between
47 and 55 years of age and during the transition, women experience multiple symptoms [1].
Postmenopause is divided into two periods; an early stage, which includes the first five years
after confirmation, and a later phase, which starts five years after the onset of menopause and
lasts until the end of life; although the latter overlaps with aging. It is important to consider stage
of menopause the woman is, because the metabolic disorders begin and are susceptible to be
modified, also the biological functions change with age, environment and the co-morbidities.
The end of the reproductive phase and the onset of menopause brings several metabolic
disorders, such as frequent vaginal infections, dyslipidemia, weight gain, visceral obesity,
hyperinsulinemia, insulin resistance, osteoporosis, glucose impaired tolerance, mild cognitive
impairment, alter coagulation, atherosclerosis, hardening of arteries, hypertension, dry skin
and mucous (burning mouth syndrome); in addition, night sweats, and mood changes [2].
Several of the aforementioned disorders have been linked to oxidative stress and inflammation.
In recent decades, it has been recognized that oxidative stress causes aging and several
pathological conditions. In this regard, the menopause has both conditions, the susceptibility
to the development diseases related to oxidative stress and aging.
Central adiposity has been linked to insulin resistance (measured using HOMA: homeostasis
model assessment) and oxidative stress (oxidized low-density lipoprotein, urinary isopros-
tanes [PGF2a], protein carbonyls, and DNA damage), coupled with the transient accumulation
of iron in postmenopausal women, which provide ideal conditions for an inflammatory and
oxidant state, which all together increases cardiovascular risk. So reducing centralized fat mass
and maintaining a favorable lipid profile, antioxidant status and iron status may be important
in protecting postmenopausal women from atherosclerotic disease [3].
Coronary artery disease, has a higher prevalence in obese postmenopausal women (with high
levels of malondialdehyde and lower superoxide dismutase), but is less observed in younger
women [4, 5].
Arterial stiffening worsens across the stages of the menopausal transition, which seems to be
mediated, by oxidative stress, particularly during the late perimenopausal and postmenopausal
periods. Through a model of rapid arterial dilating by infusion of ascorbic acid, it was found that
the postmenopausal women have minor vasodilation and higher oxidative stress [6].
Considering the significance of oxidative stress in several diseases, the research studies have
been focused at nuclear factor of transcription, Nrf2; which is considered as the most important
regulator of the antioxidant response. Nrf2 modulates expression of many genes (related to
antioxidant enzymes, inflammatory processes, tissue remodeling, carcinogenesis, and
cognitive impairment). The participation of NrF2 in menopausal events has been studied in
relationship to mainly, the vascular system, components of metabolic syndrome, osteoporosis,
and skin.
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Cardiovascular system: Nrf2 is an important component in antioxidant defenses in cardiovas-
cular diseases, such as atherosclerosis, hypertension, and heart failure. Nrf2 is also involved
in protection against oxidant stress during the processes of ischemia-reperfusion injury and
aging. However, evidence suggests that Nrf2 activity can attenuate or stimulate cardiovascular
disease processes.
Oxidative stress is an important factor to the development of endothelial dysfunction, and it has
described that the polymorphisms 653A/G (rs35652124), −651G/A (rs6706649), and −617C/A
(rs6721961) are located in the promoter region of the gene encoding NRF2 (NFE2L2) and can
participate in forearm blood flow (FBF) and forearm vascular resistance (FVR) depending on the
ethnic group. For instance, in African Americans −653G variant allele carriers had significantly
lower FBF and higher FVR. In other hand, in White Americans, −617A variant allele carriers had
significantly higher FVR. Polymorphisms within the NFE2L2 promoter were associated with
impaired forearm vasodilator responses in an endothelial-independent manner, suggesting an
important role of NRF2 in the regulation of vascular function in humans [7].
Aldosterone activates and increases Nrf2, this effect depends on the mineralocorticoid receptor
and oxidative stress. In vivo, Nrf2 activation has beneficial effects on high blood pressure
caused by aldosterone [8].
Skin: It has been observed that skin of women turns dry, during menopause, which is also
exposed to the reactive oxygen species generated during cell metabolism or by accumulation
of fat below skin. It is known that skin cells expresses the transcription factor Nrf2, before
menopause, but its expression in postmenopausal stage is unclear [9].
Osteoporosis: This is frequent in postmenopausal women. Recently findings show that this is
caused by redox imbalance, even the bone marrow presents higher levels of markers of
oxidative stress. An association between elevated hydroperoxides serum levels and reduced
bone density in postmenopausal women [10] has been reported.
This chapter presents evidence for the expression of NrF2 in alterations or diseases in meno-
pause associated with oxidative stress.
2. Metabolic disorders during menopause
Menopause is the cessation of the ovarian cycle, so it terminate ovulation and the reproductive
stage ends in women. This is because over the years, total ovogonias are reduced in the ovary
and most become refractory to the action of the pituitary gonadotropins. As a result, the levels
of estradiol are decreased; at the beginning of menopause, the menstruation become irregular
and then disappears. The symptoms of menopause are different, depending on the age, culture,
preexisting morbidities, diet, and ethnicity [11].
Hormone depletion can increase the vulnerability of tissues that are estrogen-sensitive to the
development of diseases. The principle symptoms of menopause include vasomotor symp-
toms such as night sweats, urogenital atrophy, osteopenia, and osteoporosis, psychiatric
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disorders, sexual dysfunction, dryness of skin and mucous, cardiovascular disease, cancer, and
obesity [2]. Other symptoms are polyuria, fatigue, weakness, irritability, blurred vision, thirst,
and increased appetite [12].
The most common metabolic disorders are dyslipidemia, glucose intolerance, insulin resist-
ance, hyperinsulinemia, and type 2 diabetes [13].
The lipid metabolism disorder is characterized by high levels of low density lipoprotein (LDL)
and low levels of high-density lipoprotein (HDL) [14]. This disorder makes the woman
vulnerable to cardiovascular diseases (CVD) [15]. This is due to the fact that LDL is more
susceptible to oxidation reaction, and thus are captured by the macrophage, which triggers an
inflammatory process that favors the formation of the atheromatous plaque. Moreover, HDL
has the opposite effect, but is diminished in menopause, and the protective effect is lost. Same
situation is observed in induced menopause, after a bilateral oophorectomy [16].
Another altered parameter is the plasma glucose concentration. It has been reported that a
high incidence of insulin resistance is a risk factor for developing diabetes. The other factors
that cause type 2 diabetes are obesity, sedentary lifestyle, poor eating habits, smoking, and
alcoholism [17].
After menopause, the incidence of obesity increases, even the body composition changes, from
ginecoide type (accumulation in hips and thighs), passes to android type (deposit trunk).
Although if the premenopausal women has android-type obesity, they have the same levels of
triglycerides and insulin, and risk of metabolic syndrome [18].
The effect of polycystic ovary (PO) syndrome on menopause disorders is controversial. There
are studies that support it as an additional cardiovascular risk even during premenopausal
phase, because these patients develop early arterial disease, and have a higher prevalence of
hypertension, dyslipidemia, incidence of myocardial infarction, thickness of the intima-media,
arterial stiffness, and endothelial dysfunction [19]. This is aggravated if a woman has diabetes
and dyslipidemia [20]. On the other hand, another study indicates that these patients had fewer
climacteric symptoms than controls [21], further have insulin resistance attenuated. But, there
were reports that did not find differences between postmenopausal patients with or without
pre-polycystic ovary syndrome [22].
Adipocytes (fat cells) secrete leptin, adiponectin, resistin, and ghrelin; the interaction between
them modulates the energy balance, appetite, insulin sensitivity, number and size of adipo-
cytes, among other actions that result in the metabolism of fat tissue and the production itself.
Additionally, the adipose tissue can synthesize androgens and estrogens, proinflammatory
cytokines that may have effects on blood pressure, inflammation process, and lipoprotein
metabolism [23].
It has been determined that postmenopausal women with metabolic syndrome have higher
levels of serum testosterone levels and protein binding steroid hormones (SHBG)], leptin,
resistin, insulin, and HOMA index and low levels of adiponectin. Additionally, the presence
of higher level of interleukin-6 (IL-6), and lower level of urokinase plasminogen activator (uPA)
were also documented [5]. A side effect of metabolic syndrome is the female sexual dysfunc-
tion, in both pre- and post-menopausal women [24].
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3. Estrogens and Nrf2
Most disorders and diseases developed during menopause are related to hormonal depletion
and the increase in oxidative stress, so that it is easy to assume that estrogens have antioxidant
properties. 17β-estradiol is the more potent estrogen, which has been described as capable to
inhibit the lipoperoxidation in brain homogenates in rat, induced by Fe3+, due to its lipophilicity
and polycyclic groups [25]. Also, this hormone induces the expression of superoxide dismu-
tase, glutathione peroxidase and glutathione S-transferase in peripheral blood mononuclear
cells in women who underwent total hysterectomy with bilateral salpingo-oophorectomy and
treated with estrogens as HRT [26].
Estrogens have many biological effects, so it is interesting to study compounds of dietary origin
with a similar effect. Recently, analysis of molecules similar to estrogens, which are present in
vegetables, legumes or fruits, has gained importance due to its possible antioxidant properties
as in the case of equol, which is a metabolite of genistein and daidzein, both present in broccoli.
The equol has two isomers, the form S-(−)equol and R-(+)equol, of which the first is the most
active, but only 30–50% of the population is capable to produce it. The isomer S-(−) can bind
to estrogen receptor beta, inhibit MEK, activate eNOS and AMPK and act as antioxidant. It has
been observed that this molecule releases nitric oxide, activates Nrf2 and as a consequence
promotes the expression of antioxidant genes, before being mediated by the PI3K/Akt pathway,
which has been implicated in protection against cytotoxicity, endothelial dysfunction mediated
oxidative stress.
In HUVEC cells, S-(−) equol is capable to bind to the membrane estrogen receptor (GPR30) and
to activate Nrf2and eNOS through Akt [27].
4. Proxidant conditions during menopause
Iron accumulation: The cessation of menses contributes to accumulation of iron in the body,
resulting in elevated serum ferritin. In postmenopausal women, the consequences of this fact
are controversial. For example, some studies have reported a direct relationship between iron
and atherosclerosis, cerebrovascular risk, oxidation of low density lipoproteins, high choles-
terol, inflammation, insulin resistance, and metabolic syndrome [28].
Changes of corporal composition: Greater waist circumference was associated with high oxLDL
which is independent of BMI, suggesting that the same abdominal fat mass may induce
oxidative stress, more than the general mass fat. Another study reported that the waist/hip
ratio is directly associated with LDL-C and lipid oxidation, and inversely with HDL-C, and
protein carbonyls or 8-OHdG, injury indicators [29, 30].
Studies carried out in pre and postmenopausal women, found that those who are obese have
a higher concentration of malondialdehyde; but the concentration of superoxide dismutase
enzyme was similar in all of cases [4].
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5. Nrf2 and pathologies related to oxidative stress
5.1. Osteoporosis
Epidemiological studies show that the majority of postmenopausal women are affected by
skeletal fragility caused by an excessive bone resorption [24]. Earlier, it was closely related to
oxidative stress. It is due to reduction of estrogen plasma levels and its antioxidant action on
bone [9, 31].
The estrogens activate Nrf2, which regulates the expression of antioxidant enzymes in bone
marrow. As a consequence of this reduction, Nrf2 decreases and leads to the activation of the
receptor activator of nuclear factor κB (RANKL), which promotes osteoclastogenesis [32, 33].
Moreover, the Nrf2 deficiency induces a reduction in the ratio cortical area/total area, higher
trabecular spacing, osteoclast surface in ovariectomiced mice and Nrf−/− mice [34].
5.2. Cardiovascular diseases
In humans, it has been described, three single nucleotide polymorphisms within the pro-
moter region of the gene encodes NRF2 (NFE2L2) (−653A/G, −651G/A, and −617C/A). The
−617A variant allele has major risk to develop lung injury, mediated by oxidative stress. The
NFE2L2 polymorphism has been associated to diseases with oxidative stress and inflamma-
tion, both mediated by drugs [35].
A study showed that Africans Americans carriers of −653G variant allele, have lower forearm
blood flow and higher forearm vascular, resistant; in contrast with White Americans. With
respect to −651G/A there were no differences between two populations. In White Americans,
the −617 polymorphism carriers have lower forearm blood flow (FBF) and higher forearm
vascular resistance (FVR) [6]. In clinical studies, it has been observed that African Americans
have a higher prevalence of hypertension and the decreased endothelium compared to the
white population. This predisposition to increased vascular resistance in African Americans
leads to increased shear stress on endothelial cells, which activates NAD(P)H oxidase and
mediates the formation of the oxygen species in the vascular system [36]. Accordingly, the
NADPH oxidase equilibrium nitric/superoxide/peroxynitrite oxide in endothelial cells is
shifted in favor of the reactive oxygen species in African Americans, which is associated with
a deterioration of the vasodilator capacity [37].
The negative effects of pollution, promotes an oxidative state, which is associated with
cardiopulmonary diseases. The solid matter alters lung, cardiovascular, nervous system
functions, resulting in vascular inflammation, vascular dysfunction, and increased oxidative
stress [38–41]. Nrf2 participates in resistance to hyperoxia-induced lung injury, it is also
important in the response of epithelial cells particle exposure. The data suggest an alteration
in the autonomic regulation of cardiac function during hyperoxia, which is modulated by Nrf2.
Therefore, these changes may have important implications FVR for susceptibility to adverse
cardiac response outcomes during oxidant exposure [42].
Oxidative stress is a component of the pathogenesis in many cardiovascular diseases, and
atherosclerosis, hypertension, heart collapse, and ischemia/reperfusion injury. The sources of
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reactive oxygen species (ROS) that lead to oxidative stress due to inefficiencies in the chain of
mitochondrial electron transport, NADPH oxidase and xanthine oxidase everywhere, and the
metal ions released during cell lysis [43–45].
Atherosclerosis is an inflammatory disease characterized by endothelial filtration and accu-
mulation of oxidized lipoproteins of low density (LDL), physical damage to the endothelium
(e.g., turbulent flow of blood, hypertension and/or smoking).
Susceptibility to atheroma formation is not uniform throughout the vascular system, which
can be generated by shear stress generated by oscillatory flow, not unidirectional, and turbulent
blood flow, which occurs, for example, at junctions or vessel branching points, which are the
most susceptible. Conversely, atheromas are less likely to form in the vascular regions with
unidirectional laminar blood flow. It is known, that shear-stress laminar flow into blood vessels
stimulates the release of nitric (NO) oxide, but when the flow is oscillatory, the stenosis or
branch vessels are developed. This reduces NO production and increases superoxide release,
leading to oxidative stress and the progression of atherosclerosis. Laminar flow promotes
activation of Nrf2, and the oscillatory blood flow suppresses activation of Nrf2, resulting in a
favorable environment for atherogenesis [46].
It is increasingly evident that Nrf2 is important for long-term vascular integrity and endothelial
functioning, for example, sustained release of NO and protection from apoptosis [47].
The levels of matrix metalloproteinase 9 (MMP9) are linked to plaque destabilization, which
produces acute constriction of blood vessel flow and sudden cardiac or events. The athero-
protective effect of HO-1 may be associated with the partial deletion MMP9 to maintain or
improve the stability of the plate, avoiding a coronary event or acute and potentially fatal
brain [48, 49].
However, the effect of deficiency of Nrf2 on atheromatous plaque are controversial; for
example, a study indicates that deficiency of ApoE and Nrf2 (ApoE−/−Nrf2−/−)in mice fed with
fat diet had minor area of atheromatos plaque and lower softening arterial [50, 51].
Ischemia-reperfusion has been observed in processes such as thrombosis or vasospasm,
leading to inflammatory and oxidizing conditions [52]. These conditions promote expression
of the Nrf2 oxidant, as evidenced in cell culture cardiomyocytes rat after ischemia-reperfusion
cycles, that increased mRNA and protein mRNA of Nrf2. If ischemia is lower, then Nrf2, can
attenuate oxidative stress.
During an increase in blood pressure, the renin-angiotensin system increases the concentration
of free radicals, also they contribute to this and NADPH oxidases, NOX 1 are known to activate
Nrf2 [53].
It has been documented that the diseased myocardium increases oxidative stress, may increase
susceptibility to arrhythmia by a direct toxic effect of increased necrosis and apoptosis. In a
model overload it was found that the increased expression of Nrf2 decreased myocardial
hypertrophy, cardiac fibroblasts and ROS production, the latter, most likely by modulating the
activity of Nox4 [54]. Although the sharp increase in the Nrf2 content is cardioprotective, to
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modulate the production of ROS, apparently chronic activation may have a contrary effect
called “reductive stress”, so more studies on their impact is required.
ERK's role is controversial, on the one hand it has been reported that oxidative stress index
expression of ERK, and participates in Nrf2 signaling, but studies indicate that activation of
ERK leads to apoptosis. Studies in rats and monkeys shown the reduction of the expression of
several components of the signaling pathway Nrf2 [55–57].
5.3. Skin
Estrogens modulates several actions in skin, in example, they promotes the keratinocyte
proliferation, the I and II collagen expression, and represents an antioxidant defense; but
when menopause begins, the skin suffer many changes, principally, dryness, becomes thin-
ner, decreased its elasticity, the collagen content is lower, and the vascularity is diminished
[58]. Cells are exposed to physical, chemical, mechanical and thermal factors, which can de-
velop oxidative stress, leading to changes in skin appearance, modifying cells and potential
malignancies [8].
Nrf2 is expressed in all cell lines of the epidermis. It binds to promoter regions known as
elements of antioxidant response (ARE) that transcribed genes of cytoprotective proteins and
antioxidants like glutatión S-transferase (GST), quinone reductase NAD(P)H (NQO1), UDP-
glucuronosyltransferases (UGT), epoxide hydrolase (EPHX), c glutamylcysteine ligase (GCL),
heme oxygenase-1 (HO-1), glutathione reductase the (GR), thioredoxin reductase (TrxR),
catalase (CAT) and superoxide dismutase (SOD). Nrf2 also promotes gene transcription
nonenzymatic antioxidant proteins as thioredoxin and ferritin [59].
It has been reported that low levels of ROS cause an increase in Nrf2 expression but high levels,
do not modify it, this leads to irreversible cell injury and apoptosis induction. An intermediate
level of ROS maintains control of the balance between survival and apoptosis by activating
transcription factor-NFjB [60].
The epidermis (outer skin layer) consists mainly of keratinocytes and melanocytes, Langerhans
cells and Merkel cells. Nrf2 has two effects, firstly, promotes regeneration and expression of
antioxidant enzymes [61], and secondly, it can perpetuate the survival of damaged cells by
ROS generated during aerobic metabolism, and the respiratory burst of the immune cell
system, increasing the resistance to apoptosis of cells in culture under UV ray [62]. Nrf2 can
be activated by the sulforane (obtained from broccoli and Brussels sprouts) [8].
In melanocytes, the H2O2 is generated by tyrosinase enzyme and later is metabolized by
catalase. The Nrf2 activity protects melanocytes against the effects of ROS. This effect is
associated with a higher level of melanotropine (a-MSH), this unbalanced signal redox state
arrives from the cytoplasm and begins the synthesis of molecules Nrf2 [63, 64].
The synthesis of Nrf2 is constant in melanocytes and alterations in this process, can reduce the
resistance of cells to stress, both physical and chemical, leading to cell death or carcinogenesis
[65, 66]. The Nrf2 level may be affected by hormones like estrogens. Curcumin is an extract
from turmeric root, which acts as antifibrotic in systemic scleroderma, by reducing ROS that
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2120
causes suppression of the fibrotic process in scleroderma [67, 68]. In contrast, it reduces Nrf2
activity also by antioxidants thiol and thioredoxin, since the thiol group can prevent oxidation
of Keap1, which favors the maintenance of Nrf2 in theKeap1 complex [69].
5.4. Immunological disorders
The adipose tissue is an important endocrine gland, it produces proinflammatory cytokines.
In menopause, several inflammatory conditions, such as preexist diseases and oxidative stress,
have been described, but possibly the most important factor is the centralized fat mass. In a
study that considered healthy postmenopausal women of different ethnicity higher levels of
proinflammatory markers, such as reactive C-reactive protein, interleukin-1β, and tumor
necrosis factorα, are reported. This fact is very important, because, it marked a proinflamma-
tory state associated only with the postmenopause [70].
Figure 1. Alterations and diseases observed in menopause. Several diseases present in the menopause, are related to
low levels.
The Nrf2 pathway plays a role in degenerative and immune disorders, such as atherosclerosis,
inflammatory bowel disease (IBD), diabetes, rheumatoid arthritis, HIV/acquired immunode-
ficiency (HIV/AIDS) syndrome, neurological disorders, sepsis, cancer, Alzheimer's disease and
many others [71]. Although the exact mechanism is unknown, studies in macrophages, indicate
that genes Nrf2 inhibits pro-inflammatory cytokines [72], so this mechanism must be deregu-
lated in this stage of life. Many studies on menopause are presented, but there some of them
has been related to oxidative stress, which are characterized by a decreased level of Nrf2
(Figure 1).
6. Diet and Nrf2
Changes in body composition of women may have different causes, for example, mood swings
can lead to eating disorders. Although, special diets are recommended for this stage; investi-
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gations are providing substantial information based on its recommendation in relation to the
activation of Nrf2 that can induce phytochemicals present in different foods, especially of plant
origin. Among these compounds are curcumin, sulforaphane, anthocyanins and alkyl catechol.
Lactobacilli are important too, as they contain phenolic acid decarboxylase enzyme, alkyl
catechol (Figure 2) [73–75].
Figure 2. Modulators of Nrf2. Levels of Nrf2 can increase by compounds present in vegetables such as curcumin and
broccoli.
7. Conclusions
Menopause is caused by the changes in the production of estrogens, hormones that modulate
several functions in organs and tissues, but when its blood levels are diminished, different
disorders are developed, such as, cardiovascular events, osteoporosis, dyslipidemia, changes
in corporal composition, among others. All of them have been directly related to oxidative
stress. The major regulator of this state is Nrf2, which is activated by estrogens, phytoestrogens,
and alkyl catechol. In conclusion, the oxidative stress observed during menopause and its
stages, can be modulated by activators of Nrf2, and vegetables and fruits have compounds
with similar effect.
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